Modern biomarkers as key tools in the early diagnosis and monitoring of Alzheimer's disease progression
DOI:
https://doi.org/10.12775/JEHS.2025.80.60238Keywords
Alzheimer’s disease, biomarkers, cerebrospinal fluid, neuroimaging, Aβ42, tau protein, A/T/N classification, early diagnosisAbstract
Advances in the understanding of Alzheimer’s disease (AD) pathophysiology, along with the development of neuroimaging and biomarker analysis, have enabled the detection of neurodegenerative changes even before clinical symptoms appear. This article explores the evolution of AD diagnostic criteria, with a particular focus on the pivotal role of cerebrospinal fluid biomarkers (Aβ42, t-tau, p-tau) and brain imaging techniques (MRI, PET). The A/T/N classification system and the concept of compensatory brain mechanisms are also discussed, emphasizing their relevance in early disease detection. The modern diagnostic approach, introduced by the Dubois criteria and further developed by the NIA-AA framework, allows for the identification of AD in its preclinical phase. The presence of biomarker abnormalities in asymptomatic individuals suggests a long latent period and the activation of neuroplastic compensatory processes that may delay symptom onset. The integration of biomarkers has significantly improved diagnostic accuracy, enhanced clinical trial participant selection, and enabled more precise disease monitoring. Despite these advances, effective treatments to halt or reverse disease progression remain elusive, highlighting the urgent need for further research into compensatory mechanisms, individual variability, and early therapeutic strategies.
References
1. Alzheimer Europa. Demencja w Europie Rocznik 2019: oszacowanie częstości występowania demencji w Europie. 2020.https://www.alzheimereurope.org/content/download/195515/1457520/file/FINAL%20057070%20Alzheimer%20Europe%20yearbook%202019.pdf
2. Kukull W.A., Bowen J.D. Dementia epidemiology. Med. Clin. North Am. 2002;86:573–590. doi: 10.1016/s0025-7125(02)00010-x.
3. DeKosky S.T., Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science. 2003;302:830–834. doi: 10.1126/science.1090349.
4. Dickerson B.C., Salat D.H., Greve D.N., Chua E.F., Rand-Giovannetti E., Rentz D.M., et al. Sperling RA increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005;65(3):404–411. doi: 10.1212/01.wnl.0000171450.97464.49
5. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., et al. Scheltens P research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734–746. doi: 10.1016/S1474-4422(07)70178-3.
6. Alzheimer, A. Über eigenartige Krankheitsfälle des späteren Alters. Z. Gesamte Neurol. Psychiatr. 1911, 4, 356385.
7. Tierney, M.C.; Fisher, R.H.; Lewis, A.J.; Zorzitto, M.L.; Snow, W.G.; Reid, D.W.; Nieuwstraten, P. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer’s disease: A clinicopathologic study of 57 cases. Neurology 1988, 38, 359–364.
8. Lim, A.; Tsuang, D.; Kukull, W.; Nochlin, D.; Leverenz, J.; McCormick, W.; Bowen, J.; Teri, L.; Thompson, J.; Peskind, E.R.; et al. Clinico-neuropathological correlation of Alzheimer’s disease in a community-based case series. J. Am. Geriatr. Soc. 1999, 47, 564–569.
9. Petrovitch, H.; White, L.R.; Ross, G.W.; Steinhorn, S.C.; Li, C.Y.; Masaki, K.H.; Davis, D.G.; Nelson, J.; Hardman, J.; Curb, J.D.; et al. Accuracy of clinical criteria for A Din the Honolulu-Asia Aging Study, a population-based study. Neurology 2001, 57, 226–234.
10. Varma, A.; Snowden, J.; Lloyd, J.; Talbot, P.; Mann, D.; Neary, D. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer’s disease and fronto temporal dementia. J. Neurol. Neurosurg. Psychiatry1999, 66, 184–188.
11. Kazee, A.M.; Eskin, T.A.; Lapham, L.W.; Gabriel, K.R.; McDaniel, K.D.; Hamill, R.W. Clinicopathologic correlates in Alzheimer disease: Assessment of clinical and pathologic diagnostic criteria. Alzheimer. Dis. Assoc. Disord. 1993, 7, 152–164
12. Dubois, B.; Feldman, H.H.; Jacova, C.; DeKosky, S.T.; Barberger-Gateau, P.; Cummings, J.; Delacourte, A.; Galasko, D.; Gauthier, S.; Jicha, G.; et al. Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS–ADRDA criteria. Lancet Neurol. 2007, 6, 734–746.
13. Sperling, R.A.; Aisen, P.S.; Beckett, L.A.; Bennett, D.A.; Craft, S.; Fagan, A.M.; Iwatsubo, T.; Jack, C.R.; Kaye, J.; Montine, T.J.; et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011, 7, 280–292
14. Albert, M.S.; DeKosky, S.T.; Dickson, D.W.; Dubois, B.; Feldman, H.H.; Fox, N.C.; Gamst, A.; Holtzman, D.M.; Jagust, W.J.; Petersen, R.C.; et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011, 7, 270–279.
15. McKhann, G.M.; Knopman, D.S.; Chertkow, H.; Hyman, B.T.; Jack, C.R., Jr.; Kawas, C.H.; Klunk, W.E.; Koroshetz, W.J.; Manly, J.J.; Mayeux, R.; et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011, 7, 263–269.
16. Robb, M.A.; McInnes, P.M.; Califf, R.M. Biomarkers and surrogate endpoints: Developing common terminology and definitions. Jama 2016, 315, 1107–1108.
17. Humpel, C. Identifying and validating biomarkers for Alzheimer’s disease. Trends Biotechnol. 2011, 29, 26–32.
18. Craig-Schapiro, R.; Fagan, A.M.; Holtzman, D.M. Biomarkers of Alzheimer’s disease. Neurobiol. Dis. 2009, 35, 128–140.
19. Hampel, H.; Shen, Y.; Walsh, D.M.; Aisen, P.; Shaw, L.M.; Zetterberg, H.; Trojanowski, J.Q.; Blennow, K. Biological markers of amyloid β-related mechanisms in Alzheimer’s disease. Exp. Neurol. 2010, 223, 334–346.
20. Jack, C.R.; Knopman, D.S.; Jagust, W.J.; Shaw, L.M.; Aisen, P.S.; Weiner, M.W.; Petersen, R.C.; Trojanowski, J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet. Neurol.2010, 9, 119–128. doi: 10.1016/S1474-4422(09)70299-6.
21. Jack, C.R.; Holtzman, D.M. Biomarker modeling of Alzheimer’s disease. Neuron 2013, 80, 1347–1358.
22. Dubois, B.; Hampel, H.; Feldman, H.H.; Scheltens, P.; Aisen, P.; Andrieu, S.; Bakardjian, H.; Benali, H.; Bertram, L.; Blennow, K.; et al. Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Alzheimer’s Dement. 2016, 12, 292–323.
23. Seppälä, T.T.; Nerg, O.; Koivisto, A.M.; Rummukainen, J.; Puli, L.; Zetterberg, H.; Pyykkö, O.T.; Helisalmi, S.; Alafuzoff, I.; Hiltunen, M.; et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 2012, 78, 1568–1575.
24. Tapiola, T.; Alafuzoff, I.; Herukka, S.; Parkkinen, L.; Hartikainen, P.; Soininen, H.; Pirttilä, T. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol.2009, 66, 382–389.
25. Buerger, K.; Ewers, M.; Pirttilä, T.; Zinkowski, R.; Alafuzoff, I.; Teipel, S.J.; DeBernardis, J.; Kerkman, D.; McCulloch, C.; Soininen, H.; et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain 2006, 129, 3035–3041.
26. Shaw, L.M.; Vanderstichele, H.; Knapik-Czajka, M.; Clark, C.M.; Aisen, P.S.; Petersen, R.C.; Blennow, K.; Soares, H.; Simon, A.; Lewczuk, P.; et al. Cerebro spinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann. Neurol. 2009, 65, 403–413.
27. Buchhave, P.; Minthon, L.; Zetterberg, H.; Wallin, A.K.; Blennow, K.; Hansson, O. Cerebrospinal fluid levels of β-amyloid 1–42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch. Gen. Psychiatry 2012, 69, 98–106.
28. Fagan, A.M.; Mintun, M.A.; Shah, A.R.; Aldea, P.; Roe, C.M.; Mach, R.H.; Marcus, D.; Morris, J.C.; Holtzman, D.M. Cerebrospinal fluid tau and ptau (181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer’s disease. EMBO Mol. Med. 2009, 1, 371–380.
29. Mattsson, N.; Zetterberg, H.; Hansson, O.; Andreasen, N.; Parnetti, L.; Jonsson, M.; Herukka, S.K.; van der Flier, W.M.; Blankenstein, M.A.; Ewers, M.; et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302, 385–393.
30. Fagan, A.M.; Head, D.; Shah, A.R.; Marcus, D.; Mintun, M.; Morris, J.C.; Holtzman, D.M. Decreased cerebrospinal fluid A beta(42) correlates with brain atrophy in cognitively normal elderly. Ann. Neurol. 2009, 65, 176–183.
31. Fagan, A.M.; Roe, C.M.; Xiong, C.; Mintun, M.A.; Morris, J.C.; Holtzman, D.M. Cerebrospinal fluid tau/beta-amyloid (42) ratio as a prediction of cognitive decline in non demented older adults. Arch. Neurol. 2007, 64, 343–349.
32. Schott, J.M.; Bartlett, J.W.; Fox, N.C.; Barnes, J. Alzheimer’s Disease Neuroimaging Initiative Investigators. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Ann. Neurol. 2010, 68, 825–834
33. Petrie, E.C.; Cross, D.J.; Galasko, D.; Schellenberg, G.D.; Raskind, M.A.; Peskind, E.R.; Minoshima, S. Preclinical evidence of Alzheimer changes: Convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch. Neurol. 2009, 66, 632–637.
34. Li, G.; Sokal, I.; Quinn, J.F.; Leverenz, J.B.; Brodey, M.; Schellenberg, G.D.; Kaye, J.A.; Raskind, M.A.; Zhang, J.; Peskind, E.R.; et al. CSF tau/Abeta 42 ratio for increased risk of mild cognitive impairment: A follow-upstudy. Neurology 2007, 69, 631–639
35. Skoog, I.; Davidsson, P.; Aevarsson, O.; Vanderstichele, H.; Vanmechelen, E.; Blennow, K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: A population-based study in 85-year-olds. Dement. Geriatr. Cogn. Disord. 2003, 15, 169–176.
36. Gustafson, D.R.; Skoog, I.; Rosengren, L.; Zetterberg, H.; Blennow, K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J. Neurol. Neurosurg. Psychiatry 2007, 78, 461–464.Bendlin, B.B.; Carlsson, C.M.; Johnson, S.C.; Zetterberg, H.; Blennow, K.; Willette, A.A.; Okonkwo, O.C.; Sodhi, A.; Ries, M.L.; Birdsill, A.C.; et al. CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer’s disease. PLoS ONE 2012, 7, e37720.
37. Ringman, J.M.; Younkin, S.G.; Pratico, D.; Seltzer, W.; Cole, G.M.; Geschwind, D.H.; Rodriguez-Agudelo, Y.; Schaffer, B.; Fein, J.; Sokolow, S.; et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008, 71, 85–92.
38. Ringman, J.M.; Schulman, H.; Becker, C.; Jones, T.; Bai, Y.; Immermann, F.; Cole, G.; Sokolow, S.; Gylys, K.; Geschwind, D.H.; et al. Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch. Neurol. 2012, 69, 96–104.
39. Moonis, M.; Swearer, J.M.; Dayaw, M.P.E.; George-Hyslop, P.S.; Rogaeva, E.; Kawarai, T.; Pollen, D.A. Familial Alzheimer disease: Decreases in CSF A beta 42 levels precede cognitive decline. Neurology 2005, 65, 323–325
40. Klunk, W.E.; Engler, H.; Nordberg, A.; Wang, Y.; Blomqvist, G.; Holt, D.P.; Bergström, M.; Savitcheva, I.; Huang, G.F.; Estrada, S.; et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55, 306–319.
41. Bacskai, B.J.; Frosch, M.P.; Freeman, S.H.; Raymond, S.B.; Augustinack, J.C.; Johnson, K.A.; Irizarry, M.C.; Klunk, W.E.; Mathis, C.A.; DeKosky, S.T.; et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: A case report. Arch. Neurol. 2007, 64, 431–434
42. Johnson, K.A.; Gregas, M.; Becker, J.A.; Kinnecom, C.; Salat, D.H.; Moran, E.K.; Smith, E.E.; Rosand, J.; Rentz, D.M.; Klunk, W.E.; et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann. Neurol. 2007, 62, 229–234.
43. Lockhart, A.; Lamb, J.R.; Osredkar, T.; Sue, L.I.; Joyce, J.N.; Ye, L.; Libri, V.; Leppert, D.; Beach, T.G. PIB is a non-specific imaging marker of amyloid-beta (A beta) peptide-related cerebral amyloidosis. Brain J. Neurol.2007, 130, 2607–2615.
44. Sojkova, J.; Driscoll, I.; Iacono, D.; Zhou, Y.; Codispoti, K.E.; Kraut, M.A.; Ferrucci, L.; Pletnikova, O.; Mathis, C.A.; Klunk, W.E.; et al. In vivo fibrillar β-amyloid detected using [11c] pib positron emission tomography and neuropathologic assessment in older adults. Arch. Neurol. 2011, 68, 232–240.
45. Driscoll, I.; Troncoso, J.C.; Rudow, G.; Sojkova, J.; Pletnikova, O.; Zhou, Y.; Kraut, M.A.; Ferrucci, L.; Mathis, C.A.; Klunk, W.E.; et al. Correspondence between in vivo 11C-PiB PET amyloid imaging and post-mortem, region-matched assessment of plaques. Acta Neuropathol. 2012, 124, 823–831.
46. Kantarci, K.; Yang, C.; Schneider, J.A.; Senjem, M.L.; Reyes, D.A.; Lowe, V.J.; Barnes, L.L.; Aggarwal, N.T.; Bennett, D.A.; Smith, G.E.; et al. Antemortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol. Aging 2012, 33, 878–885.
47. Ikonomovic, M.D.; Klunk, W.E.; Abrahamson, E.E.; Mathis, C.A.; Price, J.C.; Tsopelas, N.D.; Lopresti, B.J.; Ziolko, S.; Bi, W.; Paljug, W.R.; et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain J. Neurol. 2008, 131, 1630–1645.
48. Fagan, A.M.; Mintun, M.A.; Mach, R.H.; Lee, S.Y.; Dence, C.S.; Shah, A.R.; LaRossa, G.N.; Spinner, M.L.; Klunk, W.E.; Mathis, C.A.; et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A beta 42 in humans. Ann. Neurol. 2006, 59, 512–519.
49. Vlassenko, A.G.; Mintun, M.A.; Xiong, C.; Sheline, Y.I.; Goate, A.M.; Benzinger, T.L.; Morris, J.C. Amyloid-beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data. Ann. Neurol. 2011, 70, 857–861.
50. Klunk, W.E.; Price, J.C.; Mathis, C.A.; Tsopelas, N.D.; Lopresti, B.J.; Ziolko, S.K.; Bi, W.; Hoge, J.A.; Cohen, A.D.; Ikonomovic, M.D.; et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J. Neurosci. Off. J. Soc. Neurosci. 2007, 27, 6174–6184.
51. Villemagne, V.L.; Ataka, S.; Mizuno, T.; Brooks, W.S.; Wada, Y.; Kondo, M.; Jones, G.; Watanabe, Y.; Mulligan, R.; Nakagawa, M.; et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch. Neurol. 2009, 66, 1537–1544.
52. Schöll, M.; Almkvist, O.; Axelman, K.; Stefanova, E.; Wall, A.; Westman, E.; Långström, B.; Lannfelt, L.; Graff, C.; Nordberg, A.; et al. Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol. Aging 2011, 32, 1388–1399
53. Rowe, C.C.; Ng, S.; Ackermann, U.; Gong, S.J.; Pike, K.; Savage, G.; Cowie, T.F.; Dickinson, K.L.; Maruff, P.; Darby, D.; et al. Imaging β-amyloid burden in aging and dementia. Neurology 2007, 68, 1718–1725.
54. Maruyama, M.; Shimada, H.; Suhara, T.; Shinotoh, H.; Ji, B.; Maeda, J.; Zhang, M.R.; Trojanowski, J.Q.; Lee, V.M.Y.; Ono, M.; et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013, 79, 1094–1108.
55. Walji, A.M.; Hostetler, E.D.; Selnick, H.; Zeng, Z.; Miller, P.; Bennacef, I.; Salinas, C.; Connolly, B.; Gantert, L.; Holahan, M.; et al. Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A positron emission tomography (PET) imaging agent for quantification of neurofibrillary tangles (NFTs). J. Med. Chem. 2016, 59, 4778–4789.
56. Leuzy, A.; Chiotis, K.; Lemoine, L.; Gillberg, P.G.; Almkvist, O.; Rodriguez-Vieitez, E.; Nordberg, A. Tau PET imaging in neurodegenerative tauopathies—Still a challenge. Mol. Psychiatry 2019, 24, 1112–1134.
57. Firouzian, A.; Whittington, A.; Searle, G.E.; Koychev, I.; Zamboni, G.; Lovestone, S. Imaging Aβ and tau in early stage Alzheimer’s disease with [18 F] AV45 and [18 F] AV1451. EJNMMI Res. 2018, 8, 19.
58. Firouzian, A.; Whittington, A.; Searle, G.E.; Koychev, I.; Zamboni, G.; Lovestone, S.; Gunn, R.N. Deep and Frequent Phenotyping study team. PET tau and amyloid-β burden in mild Alzheimer’s disease: Divergent relationship with age, cognition, and cerebrospinal fluid biomarkers. J. Alzheimer’s Dis. 2017, 60, 283–293
59. Jagust, W.; Reed, B.; Mungas, D.; Ellis, W.; DeCarli, C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007, 69, 871–877.
60. Schwartz, W.J.; Smith, C.B.; Davidsen, L.; Savaki, H.; Sokoloff, L.; Mata, M.; Fink, D.J.; Gainer, H. Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science 1979, 205, 723–725.
61. Attwell, D.; Laughlin, S.B. An Energy Budget for Signaling in the Grey Matter of the Brain. J. Cereb. Blood Flow Metab. 2001, 21, 1133–1145.
62. Ballard, C.; Gauthier, S.; Corbett, A.; Brayne, C.; Aarsland, D.; Jones, E. Alzheimer’s disease. Lancet 2011, 377, 1019–1031
63. Scheltens, P.; Blennow, K.; Breteler, M.M.B.; de Strooper, B.; Frisoni, G.B.; Salloway, S.; Van der Flier, W.M. Alzheimer’s disease. Lancet 2016, 388, 505–517.
64. Minoshima, S.; Giordani, B.; Berent, S.; Frey, K.A.; Foster, N.L.; Kuhl, D.E. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann. Neurol. 1997, 42, 85–94.
65. Toledo, J.B.; Xie, S.X.; Trojanowski, J.Q.; Shaw, L.M. Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI. Acta Neuropathol. 2013, 126, 659–670
66. Ewers, M.; Brendel, M.; Rizk-Jackson, A.; Rominger, A.; Bartenstein, P.; Schuff, N.; Weiner, M.W. Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects. NeuroImage Clin. 2013, 4, 45–52.
67. Reiman, E.M.; Caselli, R.J.; Yun, L.S.; Chen, K.; Bandy, D.; Minoshima, S.; Thibodeau, S.N.; Osborne, D. Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N. Engl. J. Med. 1996, 334, 752–758.
68. Small, G.W.; Mazziotta, J.C.; Collins, M.T.; Baxter, L.R.; Phelps, M.E.; Mandelkern, M.A.; Kaplan, A.; La Rue, A.; Adamson, C.F.; Chang, L.; et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995, 273, 942–947.
69. Reiman, E.M.; Chen, K.; Alexander, G.E.; Caselli, R.J.; Bandy, D.; Osborne, D.; Saunders, A.M.; Hardy, J. Correlations between apolipoprotein E epsilon 4 gene dose and brain-imaging measurements of regional hypometabolism. Proc. Natl. Acad. Sci. USA 2005, 102, 8299–8302.
70. Reiman, E.M.; Chen, K.; Alexander, G.E.; Caselli, R.J.; Bandy, D.; Osborne, D.; Saunders, A.M.; Hardy, J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc. Natl. Acad. Sci. USA 2004, 101, 284–289
71. Ossenkoppele, R.; Smith, R.; Ohlsson, T.; Strandberg, O.; Mattsson, N.; Insel, P.S.; Palmqvist, S.; Hansson, O. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology 2019, 92, e601–e612.
72. Bobinski, M.; De Leon, M.J.; Wegiel, J.; Desanti, S.; Convit, A.; Saint Louis, L.A.; Rusinek, H.; Wisniewski, H.M. The histological validation of postmortem magnetic resonance imaging-determined hippocampal volume in Alzheimer’s disease. Neuroscience 2000, 95, 721–725.
73. Frisoni, G.B.; Fox, N.C.; Jack, C.R.; Scheltens, P.; Thompson, P.M. The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 2010, 6, 67–77.
74. Fiandaca, M.S.; Mapstone, M.E.; Cheema, A.K.; Federoff, H.J. The critical need for defining preclinical biomarkers in Alzheimer’s disease. Alzheimer’s Dement. 2014, 10, S196–S212
75. Den Heijer, T.; Geerlings, M.I.; Hoebeek, F.E.; Hofman, A.; Koudstaal, P.J.; Breteler, M.M.B. Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Arch. Gen. Psychiatry 2006, 63, 57–62
76. Csernansky, J.G.; Wang, L.; Swank, J.; Miller, J.P.; Gado, M.; McKeel, D.; Miller, M.I.; Morris, J.C. Preclinical detection of Alzheimer’s disease: Hippocampal shape and volume predict dementia onset in the elderly. Neuroimage 2005, 25, 783–792.
77. Martin, S.B.; Smith, C.D.; Collins, H.R.; Schmitt, F.A.; Gold, B.T. Evidence that volume of anterior medial temporal lobe is reduced in seniors destined for mild cognitive impairment. Neurobiol. Aging 2010, 31, 1099–1106.
78. Rusinek, H.; De Santi, S.; Frid, D.; Tsui, W.H.; Tarshish, C.Y.; Convit, A.; de Leon, M.J. Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology 2003, 229, 691–696.
79. Jack, C.R.; Petersen, R.C.; Xu, Y.; O’brien, P.C.; Smith, G.E.; Ivnik, R.J.; Boeve, B.F.; Tangalos, E.G.; Kokmen, E. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology2000, 55, 484–489.
80. Apostolova, L.G.; Mosconi, L.; Thompson, P.M.; Green, A.E.; Hwang, K.S.; Ramirez, A.; Mistur, R.; Tsui, W.H.; de Leon, M.J. Subregional hippocampal atrophy predicts Alzheimer’s dementia in the cognitively normal. Neurobiol. Aging 2010, 31, 1077–1088.
81. Dickerson, B.C.; Stoub, T.R.; Shah, R.C.; Sperling, R.A.; Killiany, R.J.; Albert, M.S.; Hyman, B.T.; Blacker, D.; Detoledo-Morrell, L. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology 2011, 76, 1395–1402.
82. Dickerson, B.C.; Bakkour, A.; Salat, D.H.; Feczko, E.; Pacheco, J.; Greve, D.N.; Grodstein, F.; Wright, C.I.; Blacker, D.; Rosas, H.D.; et al. The cortical signature of Alzheimer’s disease: Regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb. Cortex 2009, 19, 497–510.
83. Dickerson, B.C.; Wolk, D.A. Alzheimer’s Disease Neuroimaging Initiative. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology 2012, 78, 84–90.
84. Fox, N.C.; Crum, W.R.; Scahill, R.I.; Stevens, J.M.; Janssen, J.C.; Rossor, M.N. Imaging of onset and progression of Alzheimer’s disease with voxel-compression mapping of serial magnetic resonance images. Lancet. Lond. Engl. 2001, 358, 201–205.
85. 83.Flier J.S., Underhill L.H., Yankner B.A., Mesulam M.-M. β-Amyloid and the Pathogenesis of Alzheimer’s Disease. N. Engl. J. Med. 1991;325:1849–1857. doi: 10.1056/NEJM199112263252605.
86. Arendt T., Bigl V. Alzheimer’s diseaseas a presumptive threshold phenomenon. Neurobiol. Aging. 1987;8:552–554. doi: 10.1016/0197-4580(87)90131-X.
87. Mann D.M. The Pathogenesis and Progression of the Pathological Changes of Alzheimer’s disease. Ann. Med. 1989;21:133–136. doi: 10.3109/07853898909149200.
88. Jack C.R., Jr., Lowe V.J., Weigand S.D., Wiste H.J., Senjem M.L., Knopman D.S., Shiung M.M., Gunter J.L., Boeve B.F., Kemp B.J., et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: Implications for sequence of pathological events in Alzheimer’s disease. Brain J. Neurol. 2009;132:1355–1365. doi: 10.1093/brain/awp062.
89. Golde T.E., Schneider L.S., Koo E.H. Anti-Aβ Therapeutics in Alzheimer’s disease: The Need for a Paradigm Shift. Neuron. 2011;69:203–213. doi: 10.1016/j.neuron.2011.01.002.
90. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., et al. Cerebro spinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann. Neurol. 2009;65:403–413. doi: 10.1002/ana.21610.
91. Mintun M.A., Larossa G.N., Sheline Y.I., Dence C.S., Lee S.Y., Mach R.H., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C. 11C]PIB in a non-demented population: Potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446–452. doi: 10.1212/01.wnl.0000228230.26044.a4.
92. Aizenstein H.J., Nebes R.D., Saxton J.A., Price J.C., Mathis C.A., Tsopelas N.D., Ziolko S.K., James J.A., Snitz B.E., Houck P.R., et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 2008;65:1509–1517. doi: 10.1001/archneur.65.11.1509.
93. Savva G.M., Wharton S.B., Ince P.G., Forster G., Matthews F.E., Brayne C. Age, neuropathology, and dementia. N. Engl. J. Med. 2009;360:2302–2309. doi: 10.1056/NEJMoa0806142.
94. Knopman D.S., Parisi J.E., Salviati A., Floriach-Robert M., Boeve B.F., Ivnik R.J., Smith G.E., Dickson D.W., Johnson K.A., Petersen L.E., et al. Neuropathology of cognitively normal elderly. Journal of Neuropathology and Experimental. Neurology. 2003;62:1087–1095. doi: 10.1093/jnen/62.11.1087.
95. Lazarczyk M.J., Hof P.R., Bouras C., Giannakopoulos P. Preclinical Alzheimer’s disease: Identification of cases at risk among cognitively intact older individuals. BMC Med. 2012;10:1–13. doi: 10.1186/1741-7015-10-127.
96. Hanseeuw B.J., Betensky R.A., Jacobs H.I., Schultz A.P., Sepulcre J., Becker J.A., Cosio D.M.O., Farrell M., Quiroz Y.T., Mormino E.C., et al. Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurol. 2019;76:915–924. doi: 10.1001/jamaneurol.2019.1424.
97. Karran E., Mercken M., De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics. Nat. Rev. Drug. Discov. 2011;10:698–712. doi: 10.1038/nrd3505.
98. Rosenberg R.N. The molecular and geneticsbasis of AD: The end of the beginning. The 2000 Watenberg lecture. Neurology. 2000;54:2045–2054. doi: 10.1212/WNL.54.11.2045.
99. Fortea J., Sala-Llonch R., Bartrés-Faz D., Lladó A., Solés Padullés C., Bosch B., Antonell A., Olives J., Sanchez-Valle R., Molinuevo J.L., et al. Cognitively preserved subjects with transitional cerebrospinal fluid ß-amyloid 1-42 values have thicker cortex in Alzheimer’s disease vulnerable áreas. Biol. Psychiatry. 2011;70:183–190. doi: 10.1016/j.biopsych.2011.02.017.
100. Defrancesco M., Egger K., Marksteiner J., Esterhammer R., Hinterhuber H., Deisenhammer E.A., Schocke M. Changes in White matter integrity before conversión from mild cognitive impairment to alzheimer’s disease. PLoS ONE. 2014;9:e106062. doi: 10.1371/journal.pone.0106062.
101. Jack C.R., Jr., Bennett D.A., Blennow K., Carrillo M.C., Dunn B., Haeberlein S.B., Holtzman D.M., Jagust W., Jessen F., Karlawish J., et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018;14:535–562. doi: 10.1016/j.jalz.2018.02.018.
102. Jack C.R., Bennett D.A., Blennow K., Carrillo M.C., Feldman H.H., Frisoni G.B., Hampel H., Jagust W.J., Johnson K.A., Knopman D.S., et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539–547. doi: 10.1212/WNL.0000000000002923.
103. Jack C.R., Jr., Therneau T.M., Weigand S.D., Wiste H.J., Knopman D.S., Vemuri P., Lowe V.J., Mielke M.M., Roberts R.O., Machulda M.M., et al. Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer’s Association Research Framework. JAMA Neurol. 2019:e191971. doi: 10.1001/jamaneurol.2019.1971.
104. Silverberg N., Elliot C., Ryan L., Masliah E., Hodes R. NIA commentary on the NIA-AA Research Framework: Towards a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018;14:576–578. doi: 10.1016/j.jalz.2018.03.004.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Konrad Strużek, Kornelia Karamus, Rafał Rejmak, Martyna Borowska-Łygan, Wojciech Urban, Jakub Tomaszewski, Anna Gryc, Jakub Lipiec, Monika Grudzień
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 73
Number of citations: 0
